SAN DIEGO--(BUSINESS WIRE)--July 10, 2006--Aegis Therapeutics announces the availability for product-specific licensure of its proprietary ProTek(TM) formulation technology employing proprietary non-toxic excipients that maintain physical stability and physiological activity of protein and peptide therapeutics. ProTek(TM) permits the generation of easily manufacturable homogeneous and stable aqueous or lyophilized dosage forms of peptide and protein drugs. ProTek(TM) is applicable to all modes of administration including the injectable, intranasal, pulmonary, oral, oral cavity, and other transmucosal routes.
